ClinicalTrials.gg
Active, not recruitingNCT06632951LIVIGNO-3Updated Aug 11, 2025

Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC)

A Phase 2 interventional study of Livmoniplimab and Budigalimab in Urothelial Carcinoma, sponsored by AbbVie. Active, not recruiting at 37 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-11.

Sponsored by AbbVie · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 361 studies in Carcinoma, Transitional Cell with a site in United States — 77 open to participants now, 141 under way, 14 of them phase 3. Carcinoma, Transitional Cell · United States.

Planned enrollment
73rd of 333
150 · median 46
Started
2025
with 21 others
Phase 2
110 of 361
18 open now
Primary completion
2027-03
later than 57 of 140 live
Registered
320th of 361
by date

Among the 361 studies in Carcinoma, Transitional Cell with a site in United States, this one is the 73rd largest by planned enrollment of the 333 interventional ones that give a count, is one of 22 that started in 2025, is one of 110 in phase 2, reaches primary completion later than 57 of the 140 other live ones, and was the 320th registered.

Carcinoma, Transitional Cell

633 studies on the registry are indexed under Carcinoma, Transitional Cell; 180 are open to participants now.

Browse Carcinoma, Transitional Cell studies →

Open to participants now

77 of the 361 studies in Carcinoma, Transitional Cell with a site in United States are open now. Recruiting first, the newest first:

72 more — sign in →

All 77 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 149 Carcinoma, Transitional Cell studies recruiting now, 123 (83%) set no upper age limit and 11 (7%) stop at 75 or younger; 4 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 361 studies in Carcinoma, Transitional Cell with a site in United States, or all of them as a file.
02

Study summary

Urothelial carcinoma (UC) is the ninth most common cancer type worldwide. While the treatment of front-line metastatic urothelial carcinoma (mUC) has improved, there remains a high unmet need for effective therapies for participants who have recurrent disease and disease that has progressed after frontline treatment. The purpose of this study is to evaluate the optimized dose, adverse events, and efficacy of livmoniplimab in combination with budigalimab.

Livmoniplimab is an investigational drug being developed for the treatment of mUC. There are 3 treatment arms in this study and participants will be randomized in a 1:1:1 ratio. Participants will either receive livmoniplimab (at one of 2 different doses) in combination with budigalimab (another investigational drug), or either docetaxel, paclitaxel, or gemcitabine (based on investigator's choice). Approximately 150 adult participants will be enrolled in the study across 56 sites worldwide.

In arm 1, participants will receive intravenously (IV) infused livmoniplimab (dose A) in combination with IV infused budigalimab. In arm 2, participants will receive IV infused livmoniplimab (dose B) in combination with IV infused budigalimab. In arm 3 (control), participants will receive the investigator's choice: IV infused or injected docetaxel; IV infused or injected paclitaxel; or IV infused gemcitabine. The estimated duration of the study is up to approximately 3.5 years.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and may require frequent medical assessments, blood tests, questionnaires, and scans.

03

Conditions studied

  • Urothelial Carcinoma

Keywords

  • Urothelial Carcinoma
  • Metastatic Urothelial Carcinoma
  • Docetaxel
  • Paclitaxel
  • Gemcitabine
  • Livmoniplimab
  • Budigalimab
  • ABBV-181
  • ABBV-151
  • Cancer
  • LIVIGNO-3
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant has or cytologically confirmed urothelial carcinoma (i.e., cancer of the bladder, renal pelvis, ureter, or urethra). Mixed histologic types are allowed if urothelial (transitional cell) is the predominant histology.
  • Participant has radiologically documented disease.
  • Participant must have experienced radiographic progression or relapse on (anti-programmed cell death protein 1 [PD-1] or anti-programmed death-ligand 1 [PD-L1]) in the metastatic, adjuvant, or setting. Participant must have received at least 2 cycles of anti-PD-1 or anti-PD-L1.
  • Participants eligible for platinum must have received a platinum containing regimen (cisplatin or carboplatin) in the metastatic, locally advanced, neoadjuvant, or adjuvant setting. If platinum was administered in the neoadjuvant or adjuvant setting, participant must have progressed within 6 months of completion of treatment. Platinum ineligible participants may enroll in this study without receiving a platinum containing regimen.
  • Participant has at least 1 per (RECIST) v1.1 as determined by investigator.
  • must be at least 3 months.

Exclusion criteria

Exclusion Criteria:

  • Participant has received more than 1 prior chemotherapy regimen for urothelial cancer in setting, including chemotherapy agents planned in comparator arm.

    • Platinum based chemotherapy administered in or neoadjuvant setting will count towards this criterion if participant progressed within 6 months of completion.
    • Chemotherapy administered during concurrent chemoradiotherapy for primary cancer will not count towards this criterion.
    • The substitution of carboplatin for cisplatin does not constitute a new regimen provided no new chemotherapeutic agents were added to the regimen and no progression was noted prior to the change in platinum.
    • Antibody-drug conjugate (ADC) will not count towards this criterion.
    • Participant who previously received gemcitabine in combination with platinum in metastatic setting will be eligible to receive docetaxel or paclitaxel in comparator arm.
  • Participant has received more than 1 antibody-drug conjugate (ADC) in metastatic setting.
  • Has had prior radiation therapy within 28 days prior to first dose of study drug or who has not recovered (i.e., \<= Grade 1 or at baseline) from adverse events due to radiotherapy.
  • History of additional or history of prior malignancy, except for adequately treated basal or squamous skin cancer, or cervical carcinoma in situ without evidence of disease, or malignancy treated with curative intent and with no evidence of disease recurrence for 5 years since the initiation of that therapy.
  • Prior allogeneic stem cell or solid organ transplantation.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    Arm 1: Livmoniplimab (Dose A) + Budigalimab

    Participants will receive livmoniplimab (dose A) in combination with budigalimab, as part of the approximately 3.5 years study duration.

    Drug: Livmoniplimab · Drug: Budigalimab

  • Experimental
    Arm 2: Livmoniplimab (Dose B) + Budigalimab

    Participants will receive livmoniplimab (dose B) in combination with budigalimab, as part of the approximately 3.5 years study duration.

    Drug: Livmoniplimab · Drug: Budigalimab

  • Experimental
    Arm 3: Docetaxel, Paclitaxel, or Gemcitabine

    Participants will receive docetaxel, paclitaxel, or gemcitabine, investigator's choice, as part of the approximately 3.5 years study duration.

    Drug: Docetaxel · Drug: Paclitaxel · Drug: Gemcitabine

Interventions

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS)

    OS is defined as the time measured from randomization until death from any cause.

    Time frame: Up to Approximately 3.5 Years

Secondary outcomes

  1. Progression-Free survival (PFS)

    PFS is defined as the time measured from randomization until the first documentation of progressive disease according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 as determined by investigators or death from any cause, whichever occurs first.

    Time frame: Up to Approximately 3.5 Years

  2. Best Overall Response (BOR) per Investigator

    BOR is defined as achieving complete response (CR) or partial response (PR) according to RECIST 1.1 as determined by investigators at any time prior to subsequent anticancer therapy.

    Time frame: Up to Approximately 3.5 Years

  3. Duration of Response (DOR) per Investigator

    DOR id defined as the time from first CR/PR until the first documentation of progressive disease according to RECIST 1.1 as determined by investigators or death from any cause, whichever occurs first.

    Time frame: Up to Approximately 3.5 Years

  4. Percentage of Participants with Adverse Events (AE)s

    An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.

    Time frame: Up to Approximately 3.5 Years

  5. Percentage of Participants with Serious Adverse Events (SAE)s

    An SAE is defined as an AE that results in the death of the participant, threat to the participant's life, hospitalization, congenital abnormality, persistent or significant disability/incapacitation, or medical event requiring medical or surgical interventions to prevent a serious outcome.

    Time frame: Up to Approximately 3.5 Years

  6. Percentage of Participants with Treatment Emergent Adverse Events (TEAE)s

    The treatment-emergent period is defined as time from the date of the first dose of study drug up to 90 days after the date of the last dose of study drug, or the first date starting new anticancer therapy, whichever occurs earlier. TEAEs include all AEs that occurred or worsened during the treatment emergent period and all treatment related SAEs as assessed by investigators.

    Time frame: Up to Approximately 3.5 Years

  7. Percentage of Participants with Clinically Significant Vital Sign Measurements as Assessed by the Investigator

    Vital signs are defined as systolic and diastolic blood pressure, pulse rate, respiratory rate, and body temperature.

    Time frame: Up to Approximately 3.5 Years

  8. Percentage of Participants with Clinically Significant Laboratory Values

    Percentage of participants with clinically significant laboratory values (hematology, chemistry, coagulation, and urinalysis) as assessed by the investigator.

    Time frame: Up to Approximately 3.5 Years

  9. Percentage of Participants with Immune-Related Reactions as AEs of Special Interest

    An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.

    Time frame: Up to Approximately 3.5 Years

  10. Maximum Observed Serum Concentration (Cmax) of Livmoniplimab

    Cmax is defined as the maximum observed serum concentration of livmoniplimab.

    Time frame: Up to Approximately 3.5 Years

  11. Cmax of Budigalimab

    Cmax is defined as the maximum observed serum concentration of budigalimab.

    Time frame: Up to Approximately 3.5 Years

  12. Time to Reach Cmax (Tmax) of Livmoniplimab

    Tmax is defined as the time to reach Cmax of livmoniplimab.

    Time frame: Up to Approximately 3.5 Years

  13. Tmax of Budigalimab

    Tmax is defined as the time to reach Cmax of budigalimab.

    Time frame: Up to Approximately 3.5 Years

  14. Area Under the Serum Concentration Versus Time Curve (AUC) of Livmoniplimab

    AUC is defined as the area under the serum concentration versus time curve of livmoniplimab.

    Time frame: Up to Approximately 3.5 Years

  15. AUC of Budigalimab

    AUC is defined as the area under the serum concentration versus time curve of budigalimab.

    Time frame: Up to Approximately 3.5 Years

  16. Clearance (CL) of Livmoniplimab

    CL is defined as the Clearance of livmoniplimab.

    Time frame: Up to Approximately 3.5 Years

  17. CL of Budigalimab

    CL is defined as the Clearance of budigalimab.

    Time frame: Up to Approximately 3.5 Years

  18. Volume of Distribution (Vd) of Livmoniplimab

    Vd is defined as the volume of distribution of livmoniplimab.

    Time frame: Up to Approximately 3.5 Years

  19. Vd of Budigalimab

    Vd is defined as the volume of distribution of budigalimab.

    Time frame: Up to Approximately 3.5 Years

  20. Incidence of Anti-Drug Antibodies (ADAs) of Livmoniplimab

    Incidence of anti-drug antibodies of livmoniplimab.

    Time frame: Up to Approximately 3.5 Years

  21. ADAs of Budigalimab

    Incidence of anti-drug antibodies of budigalimab.

    Time frame: Up to Approximately 3.5 Years

  22. Incidences of Neutralizing Anti-Drug Antibodies (nADAs) of Livmoniplimab

    Incidences of neutralizing anti-drug antibodies of livmoniplimab.

    Time frame: Up to Approximately 3.5 Years

  23. Incidences of nADAs of Budigalimab

    Incidences of neutralizing anti-drug antibodies of budigalimab.

    Time frame: Up to Approximately 3.5 Years

07

Study locations

37 sites
08

References and documents

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.

Supporting information: Study protocol, Statistical analysis plan

Time frame: For details on when studies are available for sharing, visit https://vivli.org/ourmember/abbvie/

Access criteria: To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Mar 2027, 26 months after the start.

Of 121 phase 2 interventional studies under Carcinoma, Transitional Cell, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 102. This study's planned 26 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 8, 2024
First posted
Oct 9, 2024
StartActual
Jan 20, 2025
Primary completionEst.
Mar 2027
CompletionEst.
Aug 2028
Last update
Aug 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06632951
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Oct 9, 2024
Start date
Jan 20, 2025
Primary completion
Mar 2027 (estimated)
Completion
Aug 2028 (estimated)
Last update
Aug 11, 2025

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Livmoniplimab · Budigalimab · Docetaxel · Paclitaxel · Gemcitabine

Start the discussion